醫療新知 > 治療晚期攝護腺癌病患 新藥可延長生命

治療晚期攝護腺癌病患 新藥可延長生命



法新社報導,這種藥物是阿比特龍(abiraterone),楊森藥廠(Janssen Pharmaceuticals)有售,商品名為澤珂錠(Zytiga)。





根據美國國家醫學圖書館(National Library of Medicine),比例高達92%的攝護腺癌病例能夠早期發現,也就是在腫瘤擴散到身體其他部分之前。不過,大約5%左右的患者被診斷出患病時,癌細胞已經擴散,治療前景欠佳。


J&J's Zytiga Boosts Survival in New, Severe Prostate Cancers

Bloomberg – ‎Jun 3, 2017‎
Johnson & Johnson's Zytiga helps men newly diagnosed with advanced prostate cancer live longer, according to new findings that could expand use of the medication. Men who received hormone therapy, the recommended first-time treatment, plus Zytiga …

Early use of J&J's Zytiga extends prostate cancer survival

Reuters – ‎Jun 3, 2017‎
CHICAGO Adding Johnson & Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results.

'Historic' and 'practice-changing' Zytiga delivers in prostate cancer at ASCO

BioWorld Online – ‎Jun 3, 2017‎
CHICAGO – Eagerly awaited data with abiraterone (Zytiga, Johnson & Johnson) in prostate cancer (PC) are “likely to change clinical practice pretty much overnight,” American Society of Clinical Oncology (ASCO) chief medical officer Richard Schilsky told 

J&J's Zytiga slashes death risk by 38% in earlier-stage prostate cancer patients

FiercePharma – ‎Jun 3, 2017‎
CHICAGO—Johnson & Johnson may soon be able to move prostate cancer med Zytiga into an earlier disease stage, thanks to game-changing new data that rolled out Saturday at the American Society of Clinical Oncology (ASCO) annual meeting. Zytiga, in …

Data show Zytiga can boost efficacy of first-line therapy

The Pharma Letter (registration) – ‎18 hours ago‎
Top-line data from Janssen's eagerly-awaited clinical trial into Zytiga (abiraterone acetate) in combination with the standard of care for advanced prostate cancer have been released. The data show that the relative risk of death was lowered by 37%.

Janssen announces data from pivotal phase 3 LATITUDE trial of ZYTIGA

Seeking Alpha – ‎Jun 3, 2017‎
Janssen announces data from the pivotal phase 3 LATITUDE clinical trial, which showed ZYTIGA (abiraterone acetate) plus prednisone, in combination with androgen deprivation therapy ("ADT"), demonstrated a significant improvement in overall survival and …

Hope for 20000 prostate cancer patients after 'world's biggest treatment' trial

The Independent – ‎Jun 3, 2017‎
Usually, abiraterone (sold commercially as Zytiga) is given to men who have stopped responding to ADT but the study found that giving it much earlier – and in combination with ADT – had much stronger benefits. Adding abiraterone to ADT reduced the risk 

J&J's stellar prostate cancer data signals the likelihood of a broader market approval, as Pfizer rival struggles

Endpoints News – ‎Jun 3, 2017‎
CHICAGO — J&J will be looking to expand its blockbuster market for Zytiga (abiraterone) after posting stellar data at ASCO showing that the drug combined with standard hormone therapy registered a major improvement in progression-free survival among …

Study shows early Zytiga use improves prostate cancer survival

Normangee Star – ‎17 hours ago‎
Combined therapy with abiraterone acetate/prednisone plus androgen deprivation therapy (ADT) significantly improved overall survival and radiographic progression-free survival (PFS) among men with metastatic hormone-naive prostate cancer compared …

Study shows early Zytiga use improves prostate cancer survival …

pppFocus – ‎Jun 3, 2017‎
J&J will be looking to expand its blockbuster market for Zytiga (abiraterone) after posting stellar data at ASCO showing that the drug combined with standard …

Abiraterone Combo: A New Care Standard in Prostate Cancer …

MedPage Today – ‎Jun 3, 2017‎
CHICAGO — Dramatic results in two clinical trials are persuading experts here that an androgen-suppressing drug should be used earlier in men with prostate …

Prostate cancer treatment 'could help more patients'

BBC News – ‎Jun 3, 2017‎
Abiraterone, also known as Zytiga, is a hormone therapy. Unlike chemotherapy which kills the cancerous cells, it stops more testosterone from reaching the prostate gland to stifle the tumour's growth. The trial involved almost 2,000 patients. Half the 

Quickly reporting cancer complications may boost survival

AppsforPCdaily – ‎8 hours ago‎
Men who received hormone therapy, the recommended first-time treatment, plus Zytiga were about one-third less likely to die during two studies than those who got standard treatment alone, according to research presented Saturday at the American Society …


2023-07-16 9:00 上午 夏日小帆船體驗 x 漁村導賞
2023-06-20 3:00 下午 安癌與飲食宜忌-專題講座



2023年醫院管理局研討大會 創建疫後新世代醫療:持續發展.科技創新.人才匯聚
2023年醫院管理局研討大會 醫院管理局行政總裁高拔陞醫生 主題演講 2023 年 5 月 16 日 創建疫後 […]
SANTRO-CAHON-CSTRO 「新冠流行期間癌症患者的治療考慮」互動研討會完美落幕
周伯儒, 香港大學李嘉誠醫學院四年級醫學生 Chi Lin, 內布拉斯加大學醫學中心 Feng-Ming (S […]
「人類乳頭瘤病毒 (HPV) DNA檢測與子宮頸細胞檢驗 (液基薄層柏氏抹片)的合併檢測」(合併檢測) 服務
家計會推出包括HPV DNA檢測的合併檢測 能於較早期發現子宮頸癌前病變並減癌症風險 香港家庭計劃指導會 (家 […]
中大研究發現乙肝康復者的嚴重肝病併發症風險會隨時間下降 唯仍須注意患肝癌風險 建議接受長期肝癌監測
本港約54萬人患有乙型肝炎,部分人可經藥物或自身痊癒,達至「乙肝病毒表面抗原清除」,成為「乙肝康復者」。香港中 […]
中大研究發現乙肝康復者的嚴重肝病併發症風險會隨時間下降 唯仍須注意患肝癌風險 建議接受長期肝癌監測
本港約54萬人患有乙型肝炎,部分人可經藥物或自身痊癒,達至「乙肝病毒表面抗原清除」,成為「乙肝康復者」。香港中 […]
《香港百歲老人研究》 身心健康、認知及自理能力下降 研究團隊籲加強支援服務 【新聞稿2023年3月13日】 香 […]
港大生物學家揭示防止DNA受損機制 加深對癌症形成的理解
不當的細胞分裂有可能導致癌症的發生,因此科學家一直在尋找維持細胞分裂穩定的機制。最近,香港大學(港大)生物科學 […]
城大發現促使癌細胞擴散的蛋白質 望為癌症治療提供新治療靶點
香港城市大學(城大)研究團隊發現,一種名為「賴氨酸羥化酶1」(LH1)的蛋白質,是促使肝細胞癌和胰臟導管腺癌的 […]
身體不同部位的惡性腫瘤出現癌細胞轉移時,常會轉移至肺部。以傳統手術方式切除肺轉移腫瘤,很大機會造成手術創傷,而 […]
癌症病人選用新一代口服化療藥, 在家治療可降低感染風險 疫情期間,不少病人進出醫療場所接受化療都少不免擔心受到 […]
中大發現間皮瘤的女性發病率上升 高收入國家的發病率較高
間皮瘤(Mesothelioma)由於治癒率較其他癌症低,患者的五年存活率平均僅有8%,醫學界一直努力尋求間皮 […]
港大化學生物學家拆解一類「組蛋白修飾」 為開發相關抗癌新藥帶來曙光
由香港大學(港大)化學系李祥教授率領的研究團隊,與港大生物科學學院翟元樑博士及港大生物醫學學院黃永瀚博士和鮑秀 […]